id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-010585-hasoaa0k	Szekely, Yishay	Chloroquine-induced torsade de pointes in a COVID-19 patient	2020-05-05		.txt	text/plain	1336	102	57	3 In particular, the magnitude of the proarrhythmic potential of these drugs, specifically related to their QT-prolongation effects, is questioned: On the one hand, the fact chloroquine and hydroxychloroquine block the I Kr potassium-channel at the myocyte level, therefore causing QT-prolongation, is well documented. 4 that we report a case of drug-induced torsade de pointes (TdP) due to chloroquine therapy for COVID-19. The fact that our patient was receiving memantine, a drug rated as a medication with "possible risk for TdP" likely contributed to the proarrhythmic effects of chloroquine. Excessive QT prolongation, defined as prolongation to a QTc >500 msec, has already been reported for 11%-25% of COVID-19 patients treated with hydroxychloroquine/azithromycin. Clinicians should monitor COVID-19 patients when treating them with chloroquine or other QT-prolonging drugs, with special attention to females, patients with structural heart disease, baseline QT interval on ECG, concomitant use of other QT-prolonging medications, potassium or magnesium abnormalities and bradycardia.	./cache/cord-010585-hasoaa0k.txt	./txt/cord-010585-hasoaa0k.txt